H.E. Sheikh Dr Saeed bin Tahnoun Al Nahyan, inaugurated CosmeSurge’s 17th clinic. With clinics across UAE and Oman, CosmeSurge is one of the region’s most trusted brands for cosmetic and aesthetic procedures. The new clinic opened in Zakher, Al Ain, will offer unique and specialist treatments that will redefine your beauty.

NMC Healthcare's Director of Corporate Operations Strategy Clancey Po launched the latest facility, which will"...

JUBA) – A delegation from China’s Anhui Province last week signed cooperation agreements with South Sudan’s Health ministry and a university.

The agreement, officials said, aimed at strengthening health cooperation in the health sector as well as well-being of citizens.

“What we did in the past years is not enough. There is still a lot to be done"...

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) will host an R&D meeting today beginning at 12:30 p.m. EST in New York City to outline how its science-first, patient-centric strategy, diverse portfolio of approved medicines and its R&D engine is expected to drive the company’s near-term and sustained growth. In the near-term, Takeda expects that its 14 current global growth brands will generate significant momentum enabled by at least 20 additional indications and major market expansions through FY24. In the same time period, the organization anticipates delivering 12 new molecular entities with the potential for 14 launches, representing best-in-class or first-in-class therapies across its core areas of focus. Looking ahead to FY25 and beyond, Takeda’s transformative R&D engine comprising internal research capabilities and external......

Health authorities in Wau state of South Sudan say they received a consignment of medical supplies from the national health ministry last Friday.

Speaking to Radio Tamazuj, Doctor Agok Malual Akec, the head of the ministry's medical committee, confirmed that they received the consignment comprising of medical equipment and medicine.

He said the drugs and equipment"...

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the initiation of EMPULSE, the sixth Phase III study in the empagliflozin heart failure programme. The study will assess whether in-hospital administration of empagliflozin 10 mg daily improves heart failure outcomes when initiated in people hospitalised for any type of acute heart failure event once they have been stabilised. The study will include participants both with and without type 2 diabetes.

This"...

As a leader in skincare innovation worldwide, Mary Kay Inc. continued its commitment to advance skin science as a symposium sponsor at the 44th annual meeting of The Japanese Society of Investigative Dermatology (JSID). At the conference held Nov. 8 - 10 in Aomori, Japan, the symposium on skin barriers and skin redness provided a collaborative environment to share technological advances and breakthroughs on skin health.

Established in 1981, the"...

To raise awareness regarding matters surrounding men’s health and in observance of ‘Movember,’ an annual event involving the growing of moustaches all through the month of November, Fakih IVF Fertility Center has a special line-up of services rolled out for all its male patients.

As part of the services, all male patients will be provided with a free semen analysis, with an additional 15 percent discount on all IVF-ICSI packages."...

Sudan has been facing various disease outbreaks in the past months, including cholera, dengue fever, Rift Valley fever (RVF), chikungunya, and malaria. The government and humanitarian partners actively responded to the outbreaks, the UN Office for the Coordination of Humanitarian Affairs (OCHA) reports. Most complaints reaching Radio Dabanga come from the western and eastern parts of the country.

The increase of the outbreaks can be linked to the"...

ABU DHABI, 9th November, 2019 (WAM) – Abu Dhabi Fund for Development (ADFD), the leading national entity for economic development aid, participated in the foundation stone laying ceremony of the Gudele General Hospital in South Sudan. ADFD allocated AED37 million (US$10 million) towards the strategic healthcare project, located in the capital Juba.

The 60-bed hospital will cater to the residents of Juba and adjacent areas, meeting growing"...

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (Takeda) today announced the randomized, Phase 3 TOURMALINE-MM4 study met its primary endpoint of progression free survival (PFS). The trial evaluated the effect of single-agent oral NINLARO™ (ixazomib) as a first line maintenance therapy versus placebo in adult patients diagnosed with multiple myeloma not treated with stem cell transplantation. TOURMALINE-MM4 is the first industry sponsored Phase 3 trial to explore the concept of “switch” maintenance, the use of medicines not included in initial induction therapy, in this setting. NINLARO is currently not approved for this specific use. “We are very encouraged by the results of the TOURMALINE-MM4 trial and continue our forward momentum in developing maintenance options for multiple myeloma patients. Importantly, this is the third positive Phase 3 readout......